How OraVerse Works

Get back to normal faster!

Problem 1

Children and adults have a tendency to bite their lips and even the inside of their cheeks when they are numb from anesthesia. They can’t feel themselves biting their lip and so they continue (unfortunately) until they have chewed so hard they have damaged their lips and they have become swollen and sore, sometimes to the point of being cut and bleeding!

Problem 2

Adults and young people become embarrassed being numb because they can’t speak clearly, smile or even drink properly they feel uncomfortable and self-conscious. Drooling becomes an issue.

Solution: OraVerse!

Reverse numbness faster! No more swollen or bitten lips. You can go back to work or school and be ready to take on the rest of your day without the hindrance of still being numb. You’ll be ready to talk, drink and even laugh! The rest of your day will be worry free and you won’t have those embarrassing side effects from still being numb.

OraVerse makes a difference

OraVerse is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where local anesthetic containing a vasoconstrictor (link to definition) was used. In clinical trials, the patients were able to regain normal sensation twice as fast vs, the control group.

These studies* showed that on average people who are given OraVerse not only return to normal sensation twice as fast, but they can smile, speak, and drink normally sooner, and drooling is minimized.

Who has time to be numb?

When you receive an injection not only do your lips stay numb but your whole upper and lower jaw does as well! Your entire mouth can be numb sometimes for as long as 4 hours (depending on the procedure your dentist performed).

*Source: Hersh EV, Moore PA, Papas AS and colleagues. Reversal of soft-tissue local anesthesia with phentolamine mesylate in adolescents and adults. JADA 2008;139(8):1080-1093. © 2008 American Dental Association. All rights reserved. Excerpted by permission.

Minutes to return of normal sensation

Upper Lip

50 minutes
133 minutes

OraVerse Control

Lower Lip

70 minutes
155 minutes

OraVerse Control

Is OraVerse right for you?

Take Our Quiz

Take this short quiz and discuss it with your dental professional to find out if you might be a candidate for OraVerse.

TAKE THE QUIZ

Find A Dentist

Use our “Find a Dentist” map to search your area and find the dentist nearest to you who offers OraVerse.

FIND A DENTIST

OraVerse Video

Developed for PBS’s broadcasts, this segment highlights Septodont’s innovative product OraVerse.

WATCH THE VIDEO

About OraVerse

OraVerse (Phentolamine Mesylate) injection is the first and only local dental anesthesia reversal agent.

OraVerse is indicated for the reversal of soft tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. It accelerates the return to normal sensation and function following restorative and periodontal maintenance procedures. In randomized, controlled clinical trials, the median time to recovery of normal sensation in the upper lip was 50 minutes for OraVerse patients vs 133 minutes for the control and in the lower lip was 70 minutes vs 155 minutes. OraVerse is indicated for use in adults and children 6 years of age or older and weighing at least 33 lbs.

The most common adverse reaction with OraVerse is injection-site pain.

Important Safety Information

Tachycardia, bradycardia, and cardiac arrhythmias may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are uncommon with OraVerse (phentolamine mesylate), clinicians should be alert to the signs and symptoms of these events, particularly in patients with a history of cardiovascular disease. Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse, myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states.

See full prescribing information for details.